<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01770301</url>
  </required_header>
  <id_info>
    <org_study_id>ALIENOR (GINECO-OV222)</org_study_id>
    <nct_id>NCT01770301</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)</brief_title>
  <acronym>ALIENOR</acronym>
  <official_title>A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bevacizumab (called also Avastin ®) is a medicine preventing the creation of new blood&#xD;
      vessels (a process called &quot;angiogenesis&quot;). This can reduce blood flow of the tumor and then&#xD;
      decreasing the contribution of nutriments and oxygen to the cancer cells and prevent the&#xD;
      tumor from growing.&#xD;
&#xD;
      In various types of cancers, as lung, breast, colorectal and renal cancer, addition of the&#xD;
      bevacizumab to chemotherapy allowed to improve the disease outcome. The bevacizumab already&#xD;
      benefits from a marketing authorization (MMA) for these various types of cancers.&#xD;
&#xD;
      The bevacizumab has also obtained MMA for the treatment of the ovarian cancer in its most&#xD;
      frequent histological form (ovarian carcinoma). Clinical trials conducted in this indication&#xD;
      demonstrated the importance to pursue the treatment by bevacizumab after the chemotherapy is&#xD;
      ended.&#xD;
&#xD;
      This anti-angiogenic medicine is thought to be of a potential interest in sex cords- stromal&#xD;
      since this tumors are very well vascularized.&#xD;
&#xD;
      The ALIENOR study aims to explore the interest and the clinical benefit of associating&#xD;
      bevacizumab to the paclitaxel in order to treat patients suffering from recurring sex cords-&#xD;
      stromal tumor treated beforehand by platinum chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">April 2021</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical benefit of combining bevacizumab treatment to weekly paclitaxel</measure>
    <time_frame>after 6 months of treatment</time_frame>
    <description>To evaluate the clinical benefit of combining bevacizumab treatment to weekly paclitaxel measured by the non-progression rate after 6 months of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Ovarian Sex-cord Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>A - Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive paclitaxel alone at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks for 6 cycles. Thereafter, patients will be followed-up with imaging exams every 12 weeks. At the time of confirmed progression, patients could receive bevacizumab 15 mg/kg every 3 weeks for 12 months following investigator's decision. In some cases, longer therapy may be allowed after discussion with the Principal Investigator/Sponsor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Paclitaxel + Bevacizumab followed by Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive paclitaxel at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks + Bevacizumab at the dose 10 mg/kg administered by intravenous injection every 2 weeks (D1 and D15) for 6 cycles. Thereafter, patients will receive IV injection of bevacizumab 15 mg/kg every 3 weeks for up to 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>A - Paclitaxel</arm_group_label>
    <arm_group_label>B - Paclitaxel + Bevacizumab followed by Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>B - Paclitaxel + Bevacizumab followed by Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female aged ≥ 18 years at inclusion&#xD;
&#xD;
          -  Histologically confirmed diagnosis of ovarian Sex cord-stromal tumors including the&#xD;
             following cell types: granulosa cell tumours (adults and juveniles types), granulosa&#xD;
             cell-theca cell tumour, Sertoli-Leydig cell tumours, malignant steroid cell tumours,&#xD;
             gynandroblastoma, unclassified SCST and mixed tumours&#xD;
&#xD;
          -  Documented relapse of SCST defined by progression of disease (radiologic, clinic or&#xD;
             biological progression)&#xD;
&#xD;
          -  At least one measurable site of disease as defined by RECIST 1.1&#xD;
&#xD;
               -  Tumours within a previously irradiated field will be designated as &quot;non-target&quot;&#xD;
                  lesions unless progression is documented or a biopsy is obtained to confirm&#xD;
                  persistence &gt; 90 days following completion of radiotherapy.&#xD;
&#xD;
          -  Patients must have been pre-treated with at least 1 prior line of platinum-based&#xD;
             chemotherapy&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal functions including the following:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 G/L, platelet count ≥ 100 G/L, and hemoglobin ≥ 9&#xD;
                  g/dL. Prior transfusion is authorized to keep haemoglobin level to ≥9g/dL&#xD;
&#xD;
               -  AST/ALT ≤ 3 x upper limit of normal (ULN) (or ≤ 5.0 ULN if liver metastasis) and&#xD;
                  total bilirubin ≤ 1.5 ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 ULN or calculated creatinine clearance ≥ 50 mL/min&#xD;
                  according to Cockcroft formula (or to MDRD formula for patients older than 65&#xD;
                  years-old).&#xD;
&#xD;
          -  Adequate coagulation panel:&#xD;
&#xD;
               -  PT ≤ 1.2 ULN&#xD;
&#xD;
               -  aPTT ≤ 1.5 ULN&#xD;
&#xD;
               -  INR ≤ 1.5 ULN&#xD;
&#xD;
          -  Adequate neurologic function: only neuropathy (sensory and motor) grade ≤ 1 (CTCAE&#xD;
             v4.3) are allowed&#xD;
&#xD;
          -  ECOG Performance status of 0, 1, or 2 (Appendix 5)&#xD;
&#xD;
          -  Life expectancy ≥ 4 months&#xD;
&#xD;
          -  Satisfactory cardiac function&#xD;
&#xD;
          -  Ability to understand and sign informed consent and willingness to comply with the&#xD;
             study procedures before study entry&#xD;
&#xD;
          -  Women of childbearing potential* are required to have a negative serum pregnancy test&#xD;
             within 7 days prior to study treatment initiation (i.e. Cycle 1 Day 1) and are willing&#xD;
             to use adequate contraceptive method during the whole study period and for up to 6&#xD;
             months after the last treatment intake&#xD;
&#xD;
             *: Female patients who meet at least one of the following criteria are defined as&#xD;
             women of non-childbearing potential:&#xD;
&#xD;
               -  ≥ 50 years old and naturally amenorrheic for ≥ 1 year&#xD;
&#xD;
               -  Permanent premature ovarian failure confirmed by a specialist gynaecologist&#xD;
&#xD;
                    -  Previous bilateral salpingo-oophorectomy or hysterectomy&#xD;
&#xD;
                    -  XY genotype, Turner's syndrome, or uterine agenesis&#xD;
&#xD;
                    -  Female patient who do not meet at least of the above criteria are defined as&#xD;
                       women of childbearing potential&#xD;
&#xD;
          -  Covered by a medical insurance (in country where applicable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic therapy with bevacizumab&#xD;
&#xD;
          -  Active peripheral neuropathy ≥ grade 3 (NCI-CTCAE v4.3)&#xD;
&#xD;
          -  Prior history of other malignancies other than ovarian SCST (except for basal cell or&#xD;
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the&#xD;
             subjects has been free of the disease for at least 3 years or 5 years for breast&#xD;
             cancer&#xD;
&#xD;
          -  No resolution of specific toxicities related to any prior anti-cancer therapy to grade&#xD;
             ≤1, excluding alopecia, according to the NCI-CTCAE v.4.3&#xD;
&#xD;
          -  History or evidence of thrombotic or hemorrhagic disorders, including cerebro-vascular&#xD;
             accident/stroke or transient ischemic attack or sub-arachnoids' haemorrhage within 6&#xD;
             months prior to first dose of study drugs&#xD;
&#xD;
          -  Uncontrolled arterial hypertension (systolic ≥ 150 mmHg or diastolic ≥ 100 mmHg)&#xD;
             despite optimal antihypertensive therapy or clinically significant cardiovascular&#xD;
             disease including one of the following:&#xD;
&#xD;
               -  Myocardial infarction or instable angina within 6 months prior to first dose of&#xD;
                  study drugs&#xD;
&#xD;
               -  NYHA grade ≥ II congestive heart failure&#xD;
&#xD;
               -  Serious cardiac arrhythmia requiring medication&#xD;
&#xD;
               -  Peripheral vascular disease ≥ grade 3&#xD;
&#xD;
          -  History of bowel obstruction, including sub-occlusive syndrome and history of&#xD;
             abdominal fistula, gastro-intestinal perforation or intra-abdominal abscess during the&#xD;
             year prior to inclusion&#xD;
&#xD;
          -  Prior treatments:&#xD;
&#xD;
               -  Major surgical procedure, open biopsy, or significant traumatic injury within 28&#xD;
                  days prior to study inclusion or anticipation of need for major surgical&#xD;
                  procedure during the course of the study&#xD;
&#xD;
               -  Current or recent treatment with another investigational drug within 30 days of&#xD;
                  first study treatment dosing or within 6 weeks in case of prior nitrozo-urea and&#xD;
                  or mitomycin C treatment. In case of hormonotherapy , patients will be eligible&#xD;
                  if hormonotherapy is discontinued within at least 1 week before treatment&#xD;
                  initiation&#xD;
&#xD;
               -  Current or recent (within 10 days prior to randomization) chronic use of aspirin&gt;&#xD;
                  325 mg/day or use of any other inhibitor of platelet aggregation&#xD;
&#xD;
               -  Chronic treatment (i.e. &gt; 15 days) with non steroids anti-inflammatory agents&#xD;
                  unless a washout period of 15 days was observed before the inclusion.&#xD;
&#xD;
               -  Intake of granulocyte growth factor within 3 weeks before study entry&#xD;
&#xD;
          -  Presence of hematuria and proteinuria ≥ 2+ (urine dipstick). Patients with ≥ 2+&#xD;
             proteinuria on dipstick at screening should undergo a 24-hour urine collection and&#xD;
             will be eligible only if 24-h proteinuria ≤ 1 g&#xD;
&#xD;
          -  Untreated evolutive brain metastases&#xD;
&#xD;
          -  Active bacteria or fungal infection (grade ≥2, CTC AE V4.3)&#xD;
&#xD;
          -  Known HIV1, HIV2 or chronic hepatitis B or C infection&#xD;
&#xD;
          -  Hypersensitivity to Chinese hamster ovary (CHO) cell products or other recombinant&#xD;
             human or humanized antibodies&#xD;
&#xD;
          -  Any contraindications to paclitaxel treatment: for example severe hypersensitivity&#xD;
             reactions to paclitaxel, macrogolglycerol ricinoleate (polyoxyl castor oil) or to any&#xD;
             of the excipients (Ethanol Citric acid) (refer to Taxol® SPC for further details)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle RAY-COQUARD, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Léon Bérard, LYON, FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ORACLE - Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé du Confluent</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses - Croix Saint-Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre CARIO - HPCA</name>
      <address>
        <city>Plérin</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers - Hôpital de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Centre René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICL Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.arcagy.org/arcagy-organisation-et-recherche/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 15, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2013</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sex Cord-Gonadal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

